Dr. Soff discusses results from a phase II study of romiplostim in treating patients with chemotherapy-induced thrombocytopenia. The agent led to high rates of platelet count correction and reduction in transfusion needs.
Recent Articles
Demystifying Liquid Biopsies
Tumor biopsies have long been the standard method for diagnosing, monitoring, and treating cancer and, in the era of precision medicine, molecular analyses of...
How I Treat In Brief: HCT for HIV-Related Hematologic Malignancies
This month, Joseph C. Alvarnas, MD, John A. Zaia, MD, and Stephen J. Forman, MD, discuss the use of hematopoietic cell transplantation (HCT) to...
How would you manage a patient who meets morphologic, but not molecular, criteria for...
This month, Olatoyosi Odenike, MD, discusses a patient with a morphologic presentation suggestive of acute promyelocytic leukemia (APL), but with a negative PML/RARA fusion...
Every Minute Counts: Time Management Tips and Tricks for New Doctors
Jean Louise Koff, MD, offers time-management advice for early-career hematologists transitioning from training to faculty. Dr. Koff is an instructor of hematology and medical...
Modest Rise in U.S. Spending On Prescription Drugs in 2017
Spending on prescription medicines in the U.S. last year grew by only 0.6 percent, after accounting for rebates and discounts from drug makers, according...
Current Issue
April 2018, Volume 4, Issue 5
This issue features a look at the U.S. health-care system’s transition from a paper-based system to electronic health records, an introduction to a series about oncology nurse practitioners, and more.
